Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo

20253 citationsJournal Articlegold Open Access

Authors

David Rosmarin · Indiana University – Purdue University Indianapolis

Amit G. Pandya · The University of Texas Southwestern Medical Center

Thierry Passeron · Inserm

Seth Forman

Jacek Zdybski · Akademii Nauk Stosowanych im. Józefa Gołuchowskiego

Mark Amster · Partners In Care

Christina Feser · Middle Tennessee State University

Abstract

Clinicaltrials.gov identifiers, NCT04052425 (registered on August 8, 2019), NCT04057573 (registered on August 14, 2019), and NCT04530344 (registered on August 25, 2020).

Topics & Keywords

melanin and skin pigmentation Mast cells and histamine Herpesvirus Infections and Treatments

Publication Details

Published in: Dermatology and Therapy

Volume 15, Issue 12, pp. 3703-3716

DOI: 10.1007/s13555-025-01555-3

Field-Weighted Citation Impact: 3.61

Command Palette

Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo

Authors

Abstract

Topics & Keywords

Publication Details